文献速递药物不良反应与药物警戒

倾听公众并满足其信息需求:将疫苗沟通研究转化为监管指南

Listen to the public and fulfil their information interests - translating vaccine communication research findings into guidance for regulators.
PubMed 文献 · Br J Clin Pharmacol · 2018-05-31

监管机构需在药品警戒框架下将沟通与产品风险评估整合,以回应公众对疫苗安全性的关切。本文总结欧盟监管网络基于认知、决策与媒体科学沟通研究制定的指南推荐,分享研究证据并证明沟通研究对监管机构的价值。满足公众信息需求是知情决策和安全有效使用疫苗及药品的前提,也是信任监管机构承诺的基础。

要点

  • 监管沟通应主动准备并回应公众常见关切与信息需求。
  • 沟通研究可转化为监管指南,欧盟监管网络已据此制定推荐。
  • 沟通流程须与产品风险评估在药物警戒框架下整合。

核心结论

  • 监管机构应倾听公众辩论并将沟通流程与产品风险评估整合于药物警戒框架,以具体、清晰、准确的方式向公众和疫苗政策制定者提供安全证据与不确定性信息。
  • 满足公众信息需求是知情决策及安全有效使用疫苗和药品的首要前提,也是公众信任监管机构对患者和人群健康承诺的根本。

研究设计与样本

  • 本文为综述性文章,回顾尤其来自认知科学、决策科学和媒体科学的沟通研究证据,并分享欧盟监管网络制定指南的推荐内容。

主要发现

  • 对安全性的担忧和疫苗犹豫已在不同国家的部分社区出现,这要求监管机构采取新的沟通方式,从倾听公众辩论开始。
  • 欧盟监管网络基于沟通研究制定了指南,明确应通过主动和预先准备的沟通回应公众的常见关切和信息需求。
  • 该指南受到欧盟及国际论坛的欢迎,并证明沟通研究对监管机构具有价值。

关键数值与推荐

  • 指南推荐监管机构通过主动和预先准备的沟通,回应公众常见关切与信息需求。

临床怎么用

  • 监管机构应将沟通与产品风险评估整合,确保评估中回应公众关切,并以具体、清晰、准确的方式向公众和疫苗政策制定者提供安全证据与不确定性信息。
  • 监管机构信息应支持医务人员与患者沟通,帮助其传达疫苗和药品的安全有效使用信息。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Regulatory authorities have a crucial role in communicating about the vaccines they license. In terms of content and timing, their communication to the public is usually driven by data on quality, safety and efficacy. However, concerns over safety and vaccine hesitancy have emerged in some communities in various countries, and this demands a new approach to communication, starting with listening to the public debate. Reviewing communication research findings, coming in particular from the cognitive, decision-making and media sciences, constitutes one mechanism of listening and has led the European Union (EU) regulatory network to developing guidance about which common concerns and information needs of the public to address through proactive and prepared communication. The guidance has been welcomed by EU and international fora. The current article summarizes the recommendations and shares the underlying research findings, as well as a proof of concept that communication research can be valuable for regulators. It is critical that regulators integrate the communication process with product risk assessment in the framework of pharmacovigilance, to ensure that public concerns are addressed in the assessments and that information about evidence and uncertainty relating to safety is provided to the public and vaccination policy makers in a specific, clear and accurate manner. Additionally, information from regulatory authorities should support healthcare professionals in their communication with patients. Meeting the information interests of the public is the principal prerequisite for informed decisions as well as safe and effective use of vaccines and medicines overall. This is also fundamental for trust in the authorities' commitment to patient and population health.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Bahri P, Castillon Melero M. Listen to the public and fulfil their information interests - translating vaccine communication research findings into guidance for regulators. Br J Clin Pharmacol. 2018. PMID: 29573274. doi:10.1111/bcp.13587

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。